Salud financiera de hoja de balance de AC Immune
Salud financiera controles de criterios 6/6
AC Immune tiene un patrimonio de los accionistas total de CHF130.2M y una deuda total de CHF0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son CHF244.2M y CHF114.1M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
CHF 0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | CHF 157.90m |
| Patrimonio | CHF 130.17m |
| Total pasivo | CHF 114.08m |
| Activos totales | CHF 244.25m |
Actualizaciones recientes sobre salud financiera
AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business
Jun 15
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Mar 15Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth
Oct 06We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Jun 03Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
Nov 25Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation
Jul 06Recent updates
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Jul 26AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business
Jun 15Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being
Jun 15AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up
May 24AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Apr 05We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Mar 15Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth
Oct 06We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Jun 03Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
Nov 25AC Immune Non-GAAP EPS of -$0.23 in-line
Jul 28Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation
Jul 06AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans
Feb 03AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates
Jun 02Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?
May 09AC Immune reports Q1 results; outlook
Apr 28How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?
Feb 28Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts
Jan 24We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely
Jan 19
If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%
Dec 15Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues
Nov 19AC Immune EPS misses by CHF0.02, beats on revenue
Nov 13AC Immune and Wuxi Biologics boost development of TDP-43 antibodies
Nov 09AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 30Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (CHF187.6M) de ACIU superan a sus pasivos a corto plazo (CHF101.0M).
Pasivo a largo plazo: Los activos a corto plazo de ACIU (CHF187.6M) superan a sus pasivos a largo plazo (CHF13.1M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ACIU está libre de deudas.
Reducción de la deuda: ACIU no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 0.2%.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: Aunque no es rentable ACIU tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.
Pronóstico de cash runway: ACIU no es rentable, pero tiene suficiente cash runway para más de 3 años, incluso con un flujo de caja libre positivo que se reduce un 12.1% al año.